Ying Fei Li

401 total citations
13 papers, 153 citations indexed

About

Ying Fei Li is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ying Fei Li has authored 13 papers receiving a total of 153 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Genetics and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ying Fei Li's work include Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Ying Fei Li is often cited by papers focused on Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Ying Fei Li collaborates with scholars based in United States, Switzerland and India. Ying Fei Li's co-authors include Venkat Venkatasubramanian, Matthias Hoch, Sherwin K. B. Sy, Xin Wei, Kristen Hege, Michael R. Burgess, Christopher S. Seet, Amer M. Zeidan, Wendy Stock and Martin S. Tallman and has published in prestigious journals such as Blood, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Ying Fei Li

13 papers receiving 152 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ying Fei Li United States 7 64 56 34 30 27 13 153
Lukas M. Braun Germany 9 43 0.7× 67 1.2× 53 1.6× 63 2.1× 28 1.0× 11 172
Laëtitia Largeaud France 10 43 0.7× 108 1.9× 22 0.6× 76 2.5× 68 2.5× 34 211
Carola Beier Germany 6 48 0.8× 20 0.4× 48 1.4× 47 1.6× 12 0.4× 7 166
Edward Banham-Hall United Kingdom 6 82 1.3× 11 0.2× 27 0.8× 51 1.7× 33 1.2× 11 191
Uzair Ali Khan Pakistan 5 16 0.3× 40 0.7× 80 2.4× 62 2.1× 11 0.4× 14 178
Giuseppina Uccello Italy 8 31 0.5× 67 1.2× 42 1.2× 65 2.2× 37 1.4× 12 125
G. Michlmayr Austria 6 41 0.6× 41 0.7× 31 0.9× 26 0.9× 23 0.9× 15 132
Jean‐Marc Hoffmann Germany 9 103 1.6× 24 0.4× 248 7.3× 91 3.0× 21 0.8× 20 311
Louis Williams United States 9 29 0.5× 110 2.0× 67 2.0× 84 2.8× 22 0.8× 44 185
Fauzia Ullah United States 10 25 0.4× 58 1.0× 118 3.5× 66 2.2× 18 0.7× 26 210

Countries citing papers authored by Ying Fei Li

Since Specialization
Citations

This map shows the geographic impact of Ying Fei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Fei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Fei Li more than expected).

Fields of papers citing papers by Ying Fei Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Fei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Fei Li. The network helps show where Ying Fei Li may publish in the future.

Co-authorship network of co-authors of Ying Fei Li

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Fei Li. A scholar is included among the top collaborators of Ying Fei Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Fei Li. Ying Fei Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Sahasranaman, Srikumar, Xianbin Tian, Ying Fei Li, et al.. (2025). Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact. Clinical and Translational Science. 18(5). e70221–e70221. 3 indexed citations
2.
Hoch, Matthias, Felix Huth, Paul W. Manley, et al.. (2024). Clinical Pharmacology of Asciminib: A Review. Clinical Pharmacokinetics. 63(11). 1513–1528. 7 indexed citations
3.
Sy, Sherwin K. B., et al.. (2024). Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation. Clinical Pharmacokinetics. 63(9). 1301–1312. 5 indexed citations
4.
5.
Li, Ying Fei, et al.. (2022). Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase. Clinical Pharmacology & Therapeutics. 112(5). 1040–1050. 22 indexed citations
6.
7.
Abrisqueta, Pau, Juan‐Manuel Sancho, Raúl Córdoba, et al.. (2019). Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood. 134(Supplement_1). 4089–4089. 29 indexed citations
8.
9.
Li, Ying Fei, et al.. (2019). Cyclodextrin Affects Distinct Tissue Drug Disposition as a Novel Drug Delivery Vehicle. 2(1). 1 indexed citations
10.
Li, Ying Fei, Chengyue Zhang, Simon Zhou, et al.. (2018). Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. Clinical Pharmacology Advances and Applications. Volume 10. 165–174. 10 indexed citations
11.
Li, Ying Fei & Venkat Venkatasubramanian. (2017). Neural Network to Understand Process Capability and Process Intermediates Acceptance Criteria in Monoclonal Antibody Production Process. Journal of Pharmaceutical Innovation. 13(1). 36–47. 7 indexed citations
12.
Li, Ying Fei & Venkat Venkatasubramanian. (2016). Leveraging Bayesian Approach to Predict Drug Manufacturing Performance. Journal of Pharmaceutical Innovation. 11(4). 331–338. 5 indexed citations
13.
Li, Ying Fei & Venkat Venkatasubramanian. (2016). Integrating Design of Experiments and Principal Component Analysis to Reduce Downstream Cost of Goods in Monoclonal Antibody Production. Journal of Pharmaceutical Innovation. 11(4). 352–361. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lukas M. Braun Breakdown of academic impact, for papers by Laëtitia Largeaud Breakdown of academic impact, for papers by Carola Beier Breakdown of academic impact, for papers by Edward Banham-Hall Breakdown of academic impact, for papers by Uzair Ali Khan Breakdown of academic impact, for papers by Giuseppina Uccello Breakdown of academic impact, for papers by G. Michlmayr Breakdown of academic impact, for papers by Jean‐Marc Hoffmann Breakdown of academic impact, for papers by Louis Williams Breakdown of academic impact, for papers by Fauzia Ullah
Rankless by CCL
2026